77.84
전일 마감가:
$78.20
열려 있는:
$77.42
하루 거래량:
331.43K
Relative Volume:
1.13
시가총액:
$763.77M
수익:
-
순이익/손실:
$-19.80M
주가수익비율:
-31.87
EPS:
-2.4426
순현금흐름:
$-14.56M
1주 성능:
+15.15%
1개월 성능:
+26.45%
6개월 성능:
-10.27%
1년 성능:
+200.19%
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Compare DRUG vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences Inc
|
77.84 | 763.77M | 0 | -19.80M | -14.56M | -2.4426 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | Jefferies | Buy |
| 2025-09-08 | 개시 | BTIG Research | Buy |
| 2025-05-13 | 개시 | TD Cowen | Buy |
| 2025-05-07 | 개시 | Chardan Capital Markets | Buy |
| 2025-01-23 | 개시 | Piper Sandler | Overweight |
| 2025-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-01-10 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | Robert W. Baird | Outperform |
모두보기
Bright Minds Biosciences Inc 주식(DRUG)의 최신 뉴스
Bright Minds Biosciences (NASDAQ:DRUG) Shares Down 7.7%What's Next? - MarketBeat
Bright Minds Biosciences Inc Company Profile & Introduction - Moomoo
Form 13D/A BRIGHT MINDS BIOSCIENCES INC. For: 2 July By Investing.com - Investing.com Canada
Ian McDonald reports 13.6% Bright Minds (DRUG) ownership stake - Stock Titan
Best TSX Healthcare Stocks to Watch for July 2026 - Kalkine Media
Avoiding Lag: Real-Time Signals in (DRUG) Movement - Stock Traders Daily
Canadian Securities Exchange Reports January 2026 Performance Figures - The Canadian Securities Exchange (CSE)
Indivior Pharmaceuticals Inc. (INDV) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
BrightSpring Health Services, Inc. (BTSG) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
Bright Minds Biosciences Inc (DRUG) Stock Forum and Discussion - Moomoo
Bright Minds Biosciences (DRUG) Surges 3.38% as Shares Approach Resistance at $69.08ETF NAV Deviation - dars.gov.et
DRUG Forecast — Price Target — Prediction for 2027 - TradingView
Bright Minds Biosciences Inc. Actuals & Estimates (CSE:DRUG) - TradingView
Bright Minds Biosciences Inc. (DRUG) Shows Modest Uptick, Testing Key ResistanceGap Fill Strategy - dars.gov.et
$ENA Forecast — Price Prediction for 2026. Should I Buy $ENA? - Intellectia AI
Bright Minds Biosciences (DRUG) Edges Lower Near Resistance Amid Quiet TradingHull Moving Average - dars.gov.et
DRUG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Income Statement - Intellectia AI
DRUG Technical Analysis & Stock Price Forecast - Intellectia AI
Discipline and Rules-Based Execution in DRUG Response - Stock Traders Daily
Bright Minds Biosciences (DRUG) Advances 1.92% as Stock Tests Key ResistanceHigh Volume Node - dars.gov.et
Bright Minds Biosciences Inc (DRUG) Institutional Confidence - TradingKey
Bright Minds Biosciences Inc (DRUG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Bright Minds Biosciences Inc (DRUG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Bright Minds Biosciences Inc (DRUG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Bright Minds Biosciences Inc - TradingKey
Bright Minds Biosciences Inc (DRUG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Bright Minds Biosciences Inc (DRUG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Bright Minds Biosciences Inc (DRUG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Bright Minds Biosciences (DRUG) Slides 1% as Buyers and Sellers Battle Near Critical LevelsBull Flag - newsline.com
Behavioral Patterns of DRUG and Institutional Flows - Stock Traders Daily
Bright Minds Biosciences (DRUG) Surges 3.86% as Shares Test Key Resistance ZoneMomentum Trade - newsline.com
News Releases for Bright Minds Biosciences Inc. - The Canadian Securities Exchange (CSE)
Bright Minds Biosciences Dips 4.28% as Biotech Volatility ResurfacesOpening Range Breakout - newsline.com
Bright Minds Biosciences (DRUG) Inches Up as Stock Consolidates Between Key LevelsPut Call Ratio - dars.gov.et
Bright Minds Biosciences Sets March 31, 2026 AGM, Files Meeting Materials on Form 6-K - TipRanks
Bright Minds Biosciences (NASDAQ: DRUG) details 2026 AGM, board nominees and auditor - Stock Titan
H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data - Investing.com UK
Bright Minds Biosciences Sets March 31, 2026 Date for Annual General Meeting - TipRanks
Bright Minds (DRUG) outlines 2026 AGM in Vancouver with key record dates - Stock Titan
H.C. Wainwright Maintains Bright Minds Biosciences(DRUG.US) With Buy Rating, Maintains Target Price $145 - Moomoo
H.C. Wainwright reiterates Bright Minds stock rating on epilepsy data By Investing.com - Investing.com South Africa
DRUG Reiterated by HC Wainwright & Co. -- Price Target Maintained at $145 - GuruFocus
(DRUG) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Bright Minds Biosciences to Present at Jefferies Healthcare Conference and Grants New Stock Options - The Globe and Mail
Bright Minds Biosciences (NASDAQ: DRUG) grants 109,000 options and sets June 3 Jefferies talk - Stock Titan
Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference - Weekly Voice
DRUGBright Minds Biosciences Inc Stock Price and Quote - Finviz
Bright Minds, a biotech targeting epilepsy, to speak at Jefferies health event - Stock Titan
Bright Minds Biosciences Inc (DRUG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):